Problem Solving Roundtable Discussions

These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are below.

4:15 PM - 5:15 PM


The Design and Therapeutic Application of Bispecific Antibodies

Moderator: Stephen J. Demarest, PhD, Senior Research Fellow, Protein and Antibody Engineering, Lilly Research Labs

  • The use of antibody combinations versus bispecific antibodies: Pros and Cons discussions
  • What are developability challenges of the most common bispecific antibody platforms?
  • Future areas of design / engineering to enable improved bispecifics
  • Given the vast amount of research into bispecifics, why have more not crossed the finish line?

The Selection and Development of Bi-Specific Antibodies with “Novel” Biology (1 + 1 = > 2)

Moderator: Tariq Ghayur, PhD, Distinguished Research Fellow, Foundational Immunology, AbbVie

  • Examples of bi-specific antibodies with novel biology
  • Potential HTP cell-based functional screens to identify bi-specific antibodies with novel biology
  • Optimization of the bi-specific format to achieve desired functional outcomes.
  • How to assess translational issues related to novel biology?

4:15 PM - 5:15 PM

Bispecific Antibody Case Studies & Clinical Relevance

Bispecific Antibodies in Cancer Immunotherapy

Moderator: Eva Dahlén, PhD, Senior Director, Business Development, Alligator Bioscience

  • Tumor-targeting immunomodulating compounds; pros and cons of various approaches
  • Dual immunomodulators vs combination therapy with monospecifics to corresponding targets
  • Target indication / patient population considerations for various modes of action
  • Affinity/valency considerations in relation to target expression pattern and target combination

Target Selection for Bispecific Antibodies and Related Biologics

Moderator: Rakesh Dixit, Vice President, Global Head, MedImmune, Inc.

  • Biology of the targets and their combinability
  • What targets to avoid in bispecific
  • Effector function enhancement
  • Bispecific ADCs: pros and cons
  • Managing the safety, PK-PD risks with antibody engineering

Bispecific Ab Engineering

Moderator: Mark L. Chiu, PhD, Associate Director, Process Analytical Sciences, Janssen R&D

  • Optimizing affinities for targets
  • Inclusion of Fc engineering
  • Target selection for chronic vs acute indications
  • Manufacturing